{"nctId":"NCT01625338","briefTitle":"Open-Label Study of Sofusbuvir+Ribavirin With or Without Peginterferon Alfa-2a in Subjects With Chronic HCV Infection Who Participated in Prior Gilead HCV Studies","startDateStruct":{"date":"2012-06"},"conditions":["Chronic Hepatitis C"],"count":534,"armGroups":[{"label":"SOF+RBV 12 Weeks","type":"EXPERIMENTAL","interventionNames":["Drug: SOF","Drug: RBV"]},{"label":"SOF+RBV 24 Weeks","type":"EXPERIMENTAL","interventionNames":["Drug: SOF","Drug: RBV"]},{"label":"SOF+RBV+Peg-IFN 12 Weeks","type":"EXPERIMENTAL","interventionNames":["Drug: SOF","Drug: RBV","Drug: Peg-IFN"]}],"interventions":[{"name":"SOF","otherNames":["Sovaldi®","GS-7977","PSI-7977"]},{"name":"RBV","otherNames":[]},{"name":"Peg-IFN","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Infection with HCV\n* Must have participated in a prior Gilead HCV study\n* Use of highly effective contraception methods if female of childbearing potential or sexually active male\n* Eligible patients include those in the following\n\n  * received placebo or Peg-IFN+RBV in a control arm\n  * previously participated in a Gilead-sponsored HCV study and did not attain sustained virologic response 24 weeks after discontinuation of therapy (SVR24) on a regimen containing:\n\n    * Sofosbuvir+RBV\n    * Peg-IFN and/or RBV in combination with one or more Gilead investigational direct-acting agents\n\nExclusion Criteria:\n\n* Pregnant or nursing female or male with pregnant female partner\n* Current or prior history of clinical hepatic decompensation\n* Infection with hepatitis B virus (HBV) or human immunodeficiency virus (HIV)\n* Chronic use of systemically administered immunosuppressive agents\n* Active drug abuse\n* Use of any prohibited concomitant medications","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12)","description":"SVR12 was defined as HCV RNA \\< the lower limit of quantitation (LLOQ; ie, 25 IU/mL) at 12 weeks after stopping study treatment.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"71.9","spread":null},{"groupId":"OG001","value":"77.5","spread":null},{"groupId":"OG002","value":"82.6","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants Who Permanently Discontinued Any Study Drug Due to an Adverse Event","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.9","spread":null},{"groupId":"OG001","value":"1.0","spread":null},{"groupId":"OG002","value":"3.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With SVR at 4 and 24 Weeks After Discontinuation of Therapy (SVR4 and SVR24)","description":"SVR4 and SVR 24 were defined as HCV RNA \\< LLOQ at 4 and 24 weeks after stopping study treatment, respectively.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"73.7","spread":null},{"groupId":"OG001","value":"81.5","spread":null},{"groupId":"OG002","value":"87.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"71.9","spread":null},{"groupId":"OG001","value":"76.0","spread":null},{"groupId":"OG002","value":"82.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With On-treatment Virologic Failure","description":"On-treatment virologic failure was defined as\n\n* Breakthrough (confirmed HCV RNA ≥ LLOQ after having previously had HCV RNA \\< LLOQ while on treatment), or\n* Rebound (confirmed \\> 1 log10 IU/mL increase in HCV RNA from nadir while on treatment), or\n* Non-response (HCV RNA persistently ≥ LLOQ through 8 weeks of treatment)","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.9","spread":null},{"groupId":"OG001","value":"0.5","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Viral Relapse","description":"Viral relapse was defined as HCV RNA ≥ LLOQ during the posttreatment period having achieved HCV RNA \\< LLOQ at end of treatment, confirmed with 2 consecutive values or last available posttreatment measurement.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"25.7","spread":null},{"groupId":"OG001","value":"20.6","spread":null},{"groupId":"OG002","value":"16.4","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":4,"n":114},"commonTop":["Fatigue","Headache","Nausea","Insomnia","Pruritus"]}}}